Jacobs Levy Equity Management’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-4,542
| Closed | -$222K | – | 1089 |
|
|
2025
Q2 | $222K | Sell |
4,542
-31,527
| -87% | -$1.5M | ﹤0.01% | 972 |
|
|
2025
Q1 | $1.84M | Sell |
36,069
-790,450
| -96% | -$39.4M | 0.01% | 676 |
|
|
2024
Q4 | $37.3M | Sell |
826,519
-659,778
| -44% | -$28.2M | 0.13% | 156 |
|
|
2024
Q3 | $55.1M | Sell |
1,486,297
-229,494
| -13% | -$7.68M | 0.21% | 120 |
|
|
2024
Q2 | $52.5M | Buy |
1,715,791
+109,950
| +7% | +$3.56M | 0.22% | 108 |
|
|
2024
Q1 | $46.7M | Buy |
1,605,841
+282,422
| +21% | +$7.91M | 0.21% | 118 |
|
|
2023
Q4 | $36.5M | Buy |
1,323,419
+200,721
| +18% | +$4.59M | 0.18% | 128 |
|
|
2023
Q3 | $25.2M | Buy |
1,122,698
+104,024
| +10% | +$3.87M | 0.15% | 157 |
|
|
2023
Q2 | $41.4M | Buy |
1,018,674
+295,801
| +41% | +$14.5M | 0.24% | 106 |
|
|
2023
Q1 | $35M | Sell |
722,873
-158,483
| -18% | -$7.24M | 0.21% | 123 |
|
|
2022
Q4 | $33.6M | Buy |
881,356
+328,493
| +59% | +$13.7M | 0.23% | 132 |
|
|
2022
Q3 | $27.8M | Sell |
552,863
-269,231
| -33% | -$13.2M | 0.22% | 128 |
|
|
2022
Q2 | $32.9M | Buy |
822,094
+189,064
| +30% | +$6.63M | 0.25% | 109 |
|
|
2022
Q1 | $23.6M | Buy |
633,030
+53,814
| +9% | +$2.07M | 0.16% | 161 |
|
|
2021
Q4 | $23.1M | Buy |
579,216
+148,459
| +34% | +$5.68M | 0.15% | 157 |
|
|
2021
Q3 | $16M | Buy |
430,757
+2,584
| +0.6% | +$106K | 0.11% | 222 |
|
|
2021
Q2 | $18.1M | Buy |
428,173
+290,189
| +210% | +$12.4M | 0.12% | 208 |
|
|
2021
Q1 | $6.53M | Buy |
137,984
+92,099
| +201% | +$5.47M | 0.05% | 378 |
|
|
2020
Q4 | $2.8M | Sell |
45,885
-2,060
| -4% | -$121K | 0.02% | 507 |
|
|
2020
Q3 | $2.24M | Sell |
47,945
-4,451
| -8% | -$219K | 0.02% | 501 |
|
|
2020
Q2 | $2.66M | Buy |
52,396
+24,470
| +88% | +$1.2M | 0.03% | 467 |
|
|
2020
Q1 | $1.25M | Buy |
27,926
+21,616
| +343% | +$1.09M | 0.02% | 579 |
|
|
2019
Q4 | $303K | Sell |
6,310
-200
| -3% | -$8.5K | ﹤0.01% | 853 |
|
|
2019
Q3 | $220K | Buy |
6,510
+1,500
| +30% | +$65.3K | ﹤0.01% | 827 |
|
|
2019
Q2 | $225K | Buy |
+5,010
| New | +$198K | ﹤0.01% | 861 |
|
|
2018
Q4 | – | Sell |
-12,740
| Closed | -$599K | – | 1050 |
|
|
2018
Q3 | $599K | Sell |
12,740
-1,160
| -8% | -$48K | 0.01% | 741 |
|
|
2018
Q2 | $469K | Buy |
+13,900
| New | +$433K | 0.01% | 810 |
|
|
2018
Q1 | – | Sell |
-11,850
| Closed | -$198K | – | 1047 |
|
|
2017
Q4 | $198K | Buy |
+11,850
| New | +$201K | ﹤0.01% | 907 |
|
|
2017
Q2 | – | Sell |
-25,060
| Closed | -$247K | – | 1000 |
|
|
2017
Q1 | $247K | Sell |
25,060
-3,710
| -13% | -$44.9K | 0.01% | 757 |
|
|
2016
Q4 | $314K | Buy |
+28,770
| New | +$302K | 0.01% | 762 |
|
Other funds holding PTCT
RI
AC
Jacobs Levy Equity Management's PTCT Position: Q3 2025 in Review
Jacobs Levy Equity Management sold out of PTC Therapeutics (PTCT) in Q3 2025, closing a stake of 4,542 shares — an estimated $222K sold.
Jacobs Levy Equity Management first reported a position in PTCT in Q4 2016 and held it in 30 quarters. The position peaked at $55.1M in Q3 2024. 293 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.
- Jacobs Levy Equity Management reported no remaining PTC Therapeutics position as of Q3 2025 after selling out during the quarter.
- Jacobs Levy Equity Management sold 4,542 PTC Therapeutics shares in Q3 2025, an estimated $222K.
- Jacobs Levy Equity Management first reported a position in PTC Therapeutics in Q4 2016 and held it in 30 quarters.
- Jacobs Levy Equity Management's PTC Therapeutics position peaked at $55.1M in Q3 2024.
- 293 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.
Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.